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ABSTRACT A brief account is given of various approaches
to the individualization of drug dosage, including the use of
pharmacodynamic markers, therapeutic monitoring of plas-
ma drug concentrations, genotyping, computer-guided dos-
age using ‘dashboards’, and automatic closed-loop control of
pharmacological action. The potential for linking the real pa-
tient to his or her ‘virtual twin’ through the application of
physiologically-based pharmacokinetic modeling is also
discussed.
KEY WORDS drug dosage . personalized medicine .
pharmacogenetics . physiologically-based pharmacokinetic
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ABBREVIATIONS
ADR Adverse drug reaction
BIS Bispectral index
BSA Body surface area
CYP Cytochrome P450
DDI Drug – drug interaction
EEG Electroencephalogram
TDM Therapeutic drug monitoring
VKORC1 Vitamin K epoxide reductase complex
INTRODUCTION
The process of drug dosage involves prescription by the phy-
sician, dispensing by the pharmacist and administration to or
by the patient. Ideally, the outcome in terms of therapeutic
effect and safety is evaluated by the physician who might then
adjust the dose accordingly. Several iterations may be neces-
sary to finally close this loop in a satisfactory manner. Control
engineers would consider this to be a ‘loose loop’ since it
contains human beings, whose knowledge, judgement and
behavior may not be optimal. Currently, at least in the UK,
teaching of the principles of pharmacokinetics and pharmaco-
dynamics to medical students is minimal, although clinical
pharmacist are striving to take more responsibility for drug
dosage, and patients often forget or otherwise fail to take their
medication as directed. In the move towards the introduction
of more ‘personalized drug dosage’, the direct measurement
of blood drug concentrations as a guide to drug dosage in
individual patients (so-called ‘therapeutic drug monitoring’,
TDM), point-of-care pharmacogenetic testing and the appli-
cation of computer-guided dosage using ‘dashboards’ have
been advocated as primary approaches while, particularly in
anesthesiology and critical care, methods for automatic
closed-loop control of pharmacological action have been
around for some time. Clearly, the safe and effective manage-
ment of multidrug dosage of the complex patient with multi-
ple diseases and multiple prescribers will require an integrated
view of pharmacology and therapeutics, taking account of
demographic, genetic and metabolomic factors as well as dis-
ease severity and progression. In this context, linking the real
patient to his or her ‘virtual twin’ through physiologically-
based pharmacokinetic (PBPK) (and pharmacodynamic)
modeling has the potential to predict appropriate individual-
ized drug dosage and to avoid undesired complex drug-drug
interactions. However, realizing this dream requires extensive
data from each patient if accurate outcomes are to be forecast.
ADHERENCE
In 2010 it was reported that of the 3.8 billion prescriptions
written in the USA every year, over 50% are taken incorrectly
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or not at all (1), and poor adherence to medication was esti-
mated to cost the healthcare system $290 billion annually (2).
Thus, in ambulatory patients incomplete adherence is a pri-
mary source of variability in effective drug dosage, suggesting
that improvements in medication management might over-
shadow those made by the application of, for example, genetic
knowledge (3). Advances in the development of cheap ap-
proaches to the electronic monitoring of drug intake beyond
‘chip-in-a-bottle’ to ‘chip-in-a-pill’ are a possible solution to
this problem (4). Also, especially for the treatment of diseases
where inadequate dosing can lead to resistance to therapy,
such as malaria, the development of innovative oral dosage
forms that are retained in the stomach allowing extended drug
release into the intestine promise the provision of weekly rath-
er than daily administration (5).
EXPOSURE VS RESPONSE
While variability in drug response has both pharmacokinetic
and pharmacodynamic elements, the separation of their con-
tributions is not always evident. Clearly, the ultimate response
will reflect both exposure and intrinsic activity and direct
pharmacodynamic markers have been used for many years,
such as glycemia and glycosuria and prothrombin time for
monitoring insulin and anticoagulant therapy, respectively.
With respect to the role of variable exposure, while clinicians
accept that measurement of renal function is often a prelude
to dosage adjustment, this does not necessarily extend routine-
ly with regard to other sources of variability in exposure such
as those due to drug metabolism and transport. An area in
need of further examination is the determination of the extent
of intrinsic pharmacodynamic variability (i.e., variability in
response in different patients at the same level of exposure),
allied with enhanced molecular sub-classification of disease
and its severity (6).
INTRA-SUBJECT VARIABILITY
The extent of intra-subject variability in drug exposure and
response may reflect intrinsic chronological changes in biology
as well as extrinsic influences such as feeding and exercise. The
former have been studied particularly with respect to cancer
chemotherapy, where the clinical relevance of the timing of
drug dosage has been established (7). Minor changes in the
diurnal level of hepatic CYP3A activity in healthy subjects
with standardized intake of food and drink have been de-
scribed recently using the kinetics of midazolam after intrave-
nous administration to mark enzyme activity, suggesting little
clinical significance (8). However, the hepatic extraction ratio
of midazolam is about 0.5, such that its clearance after
intravenous administration is dependent on liver blood flow
as well as intrinsic enzyme activity.
THERAPEUTIC DRUG MONITORING
The principle of using blood drug level measurement as a
marker of dosage is based on the recognition of a ‘therapeutic
range’ consistent with effective and safe exposure in the pop-
ulation. However, although TDM is implemented for a limit-
ed number of compounds with critical, reasonably well-
defined ranges of exposure, there are few prospective random-
ized data to substantiate its cost- effectiveness (9–11).
Technological advances, such as lab-on-a-chip analytical
methods, providing rapid turnover and accessibility of results
may facilitate the more widespread acceptance of TDM and
afford a broader vehicle for evaluating its worth (12).
PHARMACOGENETICS
Towards the end of the twentieth century many experts
asserted that genetic prediction of responsiveness to drugs
would reach the medical mainstream within a ten year period.
This included an assurance that genotyping for cytochromes
P450 would have a significant impact in improving the effica-
cy of all drug therapy and in reducing the incidence of adverse
drug reactions. However, as bothMark Twain and Niels Bohr
said BPrediction is very difficult, especially if it is about the
future^, and the promise of widespread clinical application
of pharmacogenetic testing remains largely unfulfilled. Such
tests may be divided into those that aid the selection of a drug
and those that aid in selecting its dosage. In general, imple-
mentation of the former has been more successful, especially
with regard to the choice of anticancer drugs based on tumour
genetics. Dose selection of anticancer drugs remains largely
determined by body weight or BSA and usually amounts to
maximum tolerated dosage, such that pharmacogenetic tests,
certainly those predicting exposure, need to have significant
added value. As with the application of TDM, evidence of cost
– benefit is a primary issue. Even when the results of random-
ize clinical trials are available, such as those on the impact of
CYP2C9 and VKORC1 genotypes on warfarin dosage, con-
flicting outcomes from either side of the Atlantic do not pro-
vide consensus with regard to clinical implementation (13, 14).
Nevertheless, continuing pharmacoeconomic assessment is
beginning to offer more clarity (15). Any implementation of
routine pharmacogenetic testing in selecting the doses of drugs
metabolized by CYP2D6 has been even more protracted.
Despite the fact that the ‘debrisoquine/sparteine polymor-
phism’, associated with large differences in exposure and often
in response between CYP2D6 ‘poor’ and ‘extensive
metabolizers’, was discovered over 40 years ago (16–19)
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routine genotyping remains confined to only a few specialist
centers.
COMPUTER-GUIDED DOSING
Early attempts at providing systematic dosage guidance
allowing for variability in exposure were based on the devel-
opment of manual nomograms such as those for gentamicin,
which took account of age, weight, sex and serum creatinine
(20). Subsequently, pharmacokinetic models have been incor-
porated into computerized systems as exemplified by the de-
velopment and routine use (although not in the USA) of target
controlled infusion pumps for intravenous anesthetics (21).
These devices employ pharmacokinetic – pharmacodynamic
link models and BET (‘Bolus-Elimination-Transfer’) functions
to approximate square-wave stepping of plasma drug concen-
tration (22–25). However, although demographic information
is accommodated, the inclusion of other features that deter-
mine variability in exposure is limited. In a wider clinical
context dashboard systems are available that improve the util-
ity of TDM information by incorporating adaptive Bayesian
approaches to the prediction of exposure, ideally linked to an
individual’s clinical and other details in his or her electronic
medical record (26, 27). These systems are run through the
‘cloud’ and are capable of including genotype data for speed-
ier optimization of dosage. They do require more than a single
trough plasma drug concentration measurement and a vali-
dated pharmacokinetic model for each drug. Currently, the
clinical use of dashboard systems is limited for all the usual
reasons related to cost-benefit, physician acceptance and re-
source allocation.
THE VIRTUAL TWIN
The application of PBPK modeling has come of age in drug
development and regulation, reflecting significant advances
over the last 15 years in the predictability of overall pharma-
cokinetic behavior and the extent of drug-drug interactions
(DDIs) from physical chemistry and human in vitro data and
the availability of dedicated software platforms and associated
data bases (28, 29). This approach integrates the selection of
stratified doses based on exposure in patient groups as a func-
tion of age, sex, weight, genotypes, race, co-medication, phar-
maceutical formulation, obesity, pregnancy and disease.
Accomodating these features, with increasing extension to bi-
ologics and linkage with pharmacodynamic models, is clearly
of benefit in understanding extremes of risk in different patient
populations. The challenge for the future is to link an individual
patient to his or her virtual twin within a PBPK modeling
framework to provide safe and effective individualized dosage
as a component of truly personalized drug therapy at the point
of care (28, 30). How else, for example, would it be possible to
adjust precisely the dosage of drug X metabolized by CYPs
1A2, 2C9 and 3A4 when a potent CYP3A4 inhibitor is added
to therapy in a pregnant lady who is a poor metabolizer ge-
notype for CYP2C9 and also has a low constitutive level of
CYP1A2? Potentially this could be done on a hand-held de-
vice with connection to the ‘cloud’ and knowledge of a ‘ther-
apeutic range’ of blood drug concentrations. As such, there-
fore, the ‘bottom-up’ PBPK approach integrating diverse
sources of prior information is different to actual TDM with
adaptive feedback (‘top-down’, based on direct measurement
of exposure) since it is predictive rather than retrospective.
Combining both ‘bottom-up’ and ‘top-down methods could
potentially have synergistic advantages in the rapid optimiza-
tion of drug dosage, especially since PBPK models are inher-
ently generic and much ‘richer’ in the incorporation of vari-
able patient features than conventional PKmodels. However,
currently there are two major limitations to the practical ap-
plication of the virtual twin concept, other than the usual ones
of evidence of cost-benefit and physician acceptance. The first
is that much work still needs to be done on incorporating the
impact of patient attributes, particularly of specific diseases, on
exposure and response (31). Secondly, for really precise pre-
dictions of exposure many disparate pieces of information
about the specific patient need to be readily available in order
to provide a sufficiently individualized profile. In this context,
for example, genotypes for enzymes and transporters will
clearly be helpful but even within these bands there remains
significant inter-subject variability in exposure and overlap
between genotypes (30). With cytochromes P450 how can
variability in oxidoreductase protein content and activity be
factored in (32, 33), what if there are no known genotypes
affecting activity strongly such as in the case of CYP3A4,
and what about epigenetic changes (34)? Clearly, it is possible
to mark specific enzyme and transporter activity using ‘cock-
tails’ of probe compounds (35, 36), including CYP3A4 activity
with a micro- or even nano-dose of midazolam (37) but, al-
though generically applicable to dosage of a range of drugs,
this is invasive and requires appropriate analytical resources
with rapid turnaround not available in all centers. Similarly,
endogenous markers are used to assess CYP3A4 activity,
namely plasma concentrations of 4 beta-hydroxycholesterol
and the urinary 6 beta-hydroxycortisol/cortisol ratio (38).
However, although they may be useful to mark changes
in CYP3A4 activity resulting from inhibition or induc-
tion, caution should be exercised in using them as
markers of absolute (basal) activity since other enzymes
/renal clearance influence their values. Indeed 4 beta-
hydroxycholesterol is mainly cleared by CYP7A1 which,
like 3A4, is regulated by PXR but, unlike 3A4, appears
to be downregulated by rifampicin rather than induced
by it leading to an increase in its elimination half- life
(39–41).
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AUTOMATIC CLOSED-LOOP CONTROL
The ultimate in dosage adjustment is an entirely closed loop
system based on continuous measurement of a clinically rele-
vant pharmacodynamic end-point with feedback to an admin-
istration device. This is exemplified by the automatic control
of blood sugar with an implanted glucose sensor and insulin
pump (42) and, more recently, using microneedles attached to
the skin (43). In anesthesiology and critical care the observa-
tion of many drug effects is virtually instantaneous, making the
application of control engineering principles with adaptive
feedback a particularly attractive possibility in this context.
Accordingly, systems for the real time closed-loop administra-
tion of intravenous anesthetic agents have and are being eval-
uated utilizing proportional-integral-derivative (PID control-
lers that seek a set point based on a processed EEG signal (BIS,
bispectral index or auditory evoked response) (44, 45). In this
way adaptive controllers are able to self-tune the control pa-
rameters during their use as they ‘learn’ more about the indi-
vidual patient. Variants of these systems also incorporate
pharmacokinetic models that select from a predetermined se-
ries of target plasma drug concentrations to produce a level of
arousal score (46). In post-operative care the use of patient-
controlled analgesia via an infusion pump is now common
(47). This is based on the reasonable premise that the patient,
rather than the doctor or the nurse, knows better as to how
much morphine he or she needs within the constraint of a set
lock-out time. With the increasing development of wireless-
based devices that allow continuous monitoring of physiolog-
ical and biochemical variables with linkage to central data
bases, it is likely that these will stimulate further developments
in tightening the loop of drug administration as part of a
greater alliance between the 3D’s (Diagnostics, Drugs and
Devices).
EPILOGUE
To the extent that many improvements in drug dosage will
depend on solutions that are inherently complex and require
special knowledge (e.g., of pharmacokinetics, pharmacody-
namics, pharmacogenetics, metabolomics), confidence in their
clinical application on the part of the prescriber will clearly
depend on appropriate performance verification and a degree
of education to allow plausibility checks. While individualized
dose predictions can never be exact minimal targets for inno-
vation might be to decrease inter-individual variability in drug
exposure to two-fold and ADR’s by half.
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